StreetInsider.com News Articles

Atossa Therapeutics closes $4.5 million registered direct offering

Fri, 12 Jun 2026 17:31:21 -0400

Atossa Therapeutics, Inc. (NASDAQ: ATOS) completed a registered direct offering that raised $4.5 million in gross proceeds before deducting placement agent fees and other offering expenses, according to a company statement.

The Seattle-based clinical-stage biopharmaceutical company sold 1,363,637 shares of common stock at $0.18 per share, along with Series A and Series B warrants to purchase an additional 1,363,637 shares each. The warrants become exercisable six months after issuance, with Series A warrants expiring after 5.5 years and Series B warrants expiring after two years.

If all warrants are exercised for cash, the company could receive up to an additional $12 million

Atossa Therapeutics closes $4.5 million registered direct offering

Fri, 12 Jun 2026 17:31:21 -0400

If all warrants are exercised for cash, the company could receive up to an additional $12 million

Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds

Fri, 12 Jun 2026 17:30:00 -0400

$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrants

SEATTLE, June 12, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced the closing of its previously announced registered direct offering of 1,363,637 shares (the "Shares") of its common stock, par value $0.18 per share ("Common Stock") (or common stock equivalents in lieu thereof), Series A warrants to

Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds

Fri, 12 Jun 2026 17:30:00 -0400

$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrants

Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds

Fri, 12 Jun 2026 17:30:00 -0400

$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrants

Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds

Fri, 12 Jun 2026 17:30:00 -0400

$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrants

Form 424B5 ATOSSA THERAPEUTICS,

Fri, 12 Jun 2026 09:17:00 -0400

si-local-file:///var/storage/secattach/20260612/26638816.html

Form 424B5 ATOSSA THERAPEUTICS,

Fri, 12 Jun 2026 09:17:00 -0400

si-local-file:///var/storage/secattach/20260612/26638816.html

Atossa Therapeutics raises $4.5 million in registered direct offering

Thu, 11 Jun 2026 08:01:45 -0400

Atossa Therapeutics Inc. (NASDAQ: ATOS) entered into a securities purchase agreement with institutional investors for a registered direct offering expected to generate $4.5 million in gross proceeds before fees and expenses.

The Seattle-based biopharmaceutical company will sell 1,363,638 shares of common stock at $0.18 per share, along with Series A and Series B warrants to purchase additional shares. The Series A warrants expire 5.5 years from issuance, while Series B warrants expire after two years. Both warrant series become exercisable six months following issuance.

If all warrants are exercised for cash, the company could receive an additional $12 million in gross proceeds,

Atossa Therapeutics raises $4.5 million in registered direct offering

Thu, 11 Jun 2026 08:01:45 -0400

If all warrants are exercised for cash, the company could receive an additional $12 million in gross proceeds,

Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds

Thu, 11 Jun 2026 08:00:00 -0400

$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrants

SEATTLE, June 11, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced that it has entered into a securities purchase agreement with institutional investors for the purchase and sale of 1,363,638 shares (the "Shares") of its common stock, par value $0.18 per share ("Common Stock") (or common stock

Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds

Thu, 11 Jun 2026 08:00:00 -0400

$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrants

Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds

Thu, 11 Jun 2026 08:00:00 -0400

$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrants

Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds

Thu, 11 Jun 2026 08:00:00 -0400

$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrants

Form 8-K ATOSSA THERAPEUTICS, For: Jun 10

Thu, 11 Jun 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260611/26632812.html

Form 8-K ATOSSA THERAPEUTICS, For: Jun 10

Thu, 11 Jun 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260611/26632812.html

Atossa presents preclinical data on breast cancer drug at ASCO 2026

Wed, 27 May 2026 08:30:44 -0400

Atossa Therapeutics Inc (NASDAQ: ATOS) announced two abstracts featuring its drug candidate (Z)-endoxifen have been accepted for presentation at the 2026 American Society of Clinical Oncology Annual Meeting, scheduled for May 29 to June 2 in Chicago.

The first abstract presents preclinical data showing (Z)-endoxifen demonstrated estrogen receptor inhibition across ESR1 mutations associated with endocrine resistance in breast cancer. In laboratory studies using MCF-7 breast cancer cells, the drug reduced estrogen receptor activity to 16-26% of control levels. The compound maintained consistent inhibition across key ESR1 mutations including Y537N, Y537S, and D538G.

The second abstract describes the ongoing EVANGELINE Phase 2 trial,

Atossa presents preclinical data on breast cancer drug at ASCO 2026

Wed, 27 May 2026 08:30:44 -0400

The second abstract describes the ongoing EVANGELINE Phase 2 trial,

Atossa presents preclinical data on breast cancer drug at ASCO 2026

Wed, 27 May 2026 08:30:44 -0400

The second abstract describes the ongoing EVANGELINE Phase 2 trial,

Atossa presents preclinical data on breast cancer drug at ASCO 2026

Wed, 27 May 2026 08:30:44 -0400

The second abstract describes the ongoing EVANGELINE Phase 2 trial,

Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial

Wed, 27 May 2026 08:30:00 -0400

Preclinical Data Abstract Demonstrates Robust Estrogen Receptor (ER) Inhibition in ESR1-Mutant Breast Cancer Models at Clinically Relevant Concentrations

Trial-in-Progress Abstract Details Ongoing Phase 2 EVANGELINE Study of (Z)-Endoxifen Plus Goserelin as Neoadjuvant Therapy in Premenopausal Women With ER+/HER2- Breast Cancer

SEATTLE, May 27, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significant unmet medical need, today announced that two abstracts featuring (Z)-endoxifen have been accepted for presentation at the 2026

Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial

Wed, 27 May 2026 08:30:00 -0400

Preclinical Data Abstract Demonstrates Robust Estrogen Receptor (ER) Inhibition in ESR1-Mutant Breast Cancer Models at Clinically Relevant Concentrations

Trial-in-Progress Abstract Details Ongoing Phase 2 EVANGELINE Study of (Z)-Endoxifen Plus Goserelin as Neoadjuvant Therapy in Premenopausal Women With ER+/HER2- Breast Cancer

Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial

Wed, 27 May 2026 08:30:00 -0400

Preclinical Data Abstract Demonstrates Robust Estrogen Receptor (ER) Inhibition in ESR1-Mutant Breast Cancer Models at Clinically Relevant Concentrations

Trial-in-Progress Abstract Details Ongoing Phase 2 EVANGELINE Study of (Z)-Endoxifen Plus Goserelin as Neoadjuvant Therapy in Premenopausal Women With ER+/HER2- Breast Cancer

Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial

Wed, 27 May 2026 08:30:00 -0400

Preclinical Data Abstract Demonstrates Robust Estrogen Receptor (ER) Inhibition in ESR1-Mutant Breast Cancer Models at Clinically Relevant Concentrations

Trial-in-Progress Abstract Details Ongoing Phase 2 EVANGELINE Study of (Z)-Endoxifen Plus Goserelin as Neoadjuvant Therapy in Premenopausal Women With ER+/HER2- Breast Cancer

Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial

Wed, 27 May 2026 08:30:00 -0400

Preclinical Data Abstract Demonstrates Robust Estrogen Receptor (ER) Inhibition in ESR1-Mutant Breast Cancer Models at Clinically Relevant Concentrations

Trial-in-Progress Abstract Details Ongoing Phase 2 EVANGELINE Study of (Z)-Endoxifen Plus Goserelin as Neoadjuvant Therapy in Premenopausal Women With ER+/HER2- Breast Cancer